Skip to main content
Top

28-04-2017 | Osteoarthritis | Review | Article

Wnt Signaling in Osteoarthritis: a 2017 Update

Journal: Current Treatment Options in Rheumatology

Authors: Nancy E. Lane, MD, Maripat Corr, MD, Naomi Baer, Yusuf Yazici, MD

Publisher: Springer International Publishing

Abstract

Osteoarthritis is a progressive degenerative disease of the joints in which the articular cartilage within the joints deteriorates with associated juxta-articular bone formation. While the etiology of OA is still under investigation, preclinical studies have determined that the Wnt/β-catenin signaling and bone morphogenic signaling pathways are important for the formation and repair of the joint tissues, and the effects are on both the phenotype and function of the joint tissue cells. In addition, individuals with polymorphisms in the gene, FRZB, that codes for the wnt signaling protein secreted frizzled related protein 3 (sFRP3) have higher risk of developing OA. A number of proof-of-concept preclinical studies have been performed on inhibitors of the Wnt signaling pathway, and have altered the disease progression. Proof of concept studies assessing the regenerative capacity of mesenchymal stem cells as treatments for painful knee OA have reported both encouraging and discouraging results. Therefore, the identification of the molecular pathways that are responsible for joint formation and repair has led to the development of new novel interventions for the treatment of OA that are now entering clinical trials. The ability to slow or reverse the progression of osteoarthritis may soon be within our reach.
Literature
1.
Bondeson J. Are we moving in the right direction with osteoarthritis drug discovery? Expert Opin Ther Targets. 2011;15:1355–68.CrossRefPubMed
2.
Pulsatelli L, Addimanda O, Brusi V, Pavloska B, Meliconi R. New findings in osteoarthritis pathogenesis: therapeutic implications. Ther Adv Chronic Dis. 2012;4:23–43.CrossRef
3.
Staines KA, Macrae VE, Farquharson C. Cartilage development and degeneration: a Wnt Wnt situation. Cell Biochem Funct. 2012;30:633–42.CrossRefPubMed
4.
Lories RJ, Corr M, Lane NE. To Wnt or not to Wnt: the bone and joint health dilemma. Nat Rev Rheumatol. 2013;9:328–39.CrossRefPubMedPubMedCentral
5.
Usami Y, Gunawardena AT, Iwamoto M, Enomoto-iwamoto M. HHS public access. Lab Investig. 2016;15:157–76.
6.
Davatchi F, Sadeghi Abdollahi B, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis. 2011;14:211–5.CrossRefPubMed
7.
Koh Y-G, Choi Y-J. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee. 2012;19:902–7.CrossRefPubMed
8.
Wong KL, Lee KBL, Tai BC, Law P, Lee EH, Hui JHP. Injectable cultured bone marrow–derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years’ follow-up. Arthrosc J Arthrosc Relat Surg. 2013;29:2020–8.CrossRef
9.
Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, et al. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. Transplantation. 2013;95:1535–41.CrossRefPubMed
10.
Jo C, Lee Y, SHIN W. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32:1254–66.CrossRefPubMed
11.
Vangsness T, Farr J, Boyd J, Dellaero DT, Mills CR, Leroux-Williams M. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy. J Bone Jt Surg. 2014;96:90–8.CrossRef
12.
Lambert C, Dubuc JE, Montell E, Vergés J, Munaut C, Noël A, et al. Gene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane. Arthritis Rheumatol. 2014;66:960–8.CrossRefPubMedPubMedCentral
13.
García-Ibarbia C, Pérez-Castrillón JL, Ortiz F, Velasco J, Zarrabeitia MT, Sumillera M, et al. Wnt-related genes and large-joint osteoarthritis: association study and replication. Rheumatol Int. 2013;33:2875–80.CrossRefPubMed
14.
Xu Y, Barter MJ, Swan DC, Rankin KS, Rowan AD, Santibanez-Koref M, et al. Identification of the pathogenic pathways in osteoarthritic hip cartilage: commonality and discord between hip and knee OA. Osteoarthr Cartil. 2012;20:1029–38.CrossRefPubMed
15.
Peng X, Yang L, Chang H, Dai G, Wang F, Duan X, et al. Wnt/β-catenin signaling regulates the proliferation and differentiation of mesenchymal progenitor cells through the p53 pathway. PLoS One. 2014;9:1–7. doi:10.​1371/​journal.​pone.​0097283.
16.
Van Den Bosch MH, Blom AB, Sloetjes AW, Koenders MI, Van De Loo FA, Van Den Berg WB, et al. Induction of canonical Wnt signaling by synovial overexpression of selected Wnts leads to protease activity and early osteoarthritis-like cartilage damage. Am J Pathol American Society for Investigative Pathology. 2015;185:1970–80.
17.
Papathanasiou I, Malizos KN, Tsezou A. Bone morphogenic protein-2-induced Wnt/B-catenin signalling pathway activation through enhanced low-density-lipoprotein receptor-related protein 5 catabolic activity contributes to hypertrophy in osteoarthritic chondrocytes. Arthritis Res Ther. 2012;14:R82.CrossRefPubMedPubMedCentral
18.
Miclea RL, Siebelt M, Finos L, Goeman JJ, Löwik CWGM, Oostdijk W, et al. Inhibition of Gsk3β in cartilage induces osteoarthritic features through activation of the canonical Wnt signaling pathway. Osteoarthr Cartil Elsevier Ltd. 2011;19:1363–72.CrossRef
19.
Abed É, Chan TF, Delalandre A, Martel-Pelletier J, Pelletier JP, Lajeunesse D. R-spondins are newly recognized players in osteoarthritis that regulate Wnt signaling in osteoblasts. Arthritis Rheum. 2011;63:3865–75.CrossRefPubMed
20.
Fernandes AM, Herlofsen SR, Karlsen TA, Küchler AM, Fløisand Y, Brinchmann JE. Similar properties of chondrocytes from osteoarthritis joints and mesenchymal stem cells from healthy donors for tissue engineering of articular cartilage. PLoS One. 2013;8:e62994.CrossRefPubMedPubMedCentral
21.
Funck-Brentano T, Bouaziz W, Marty C, Geoffroy V, Hay E, Cohen-Solal M. Dkk-1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis in mice. Arthritis Rheumatol. 2014;66:3028–39.CrossRefPubMed
22.
Weng LH, Wang CJ, Ko JY, Sun YC, Wang FS. Control of Dkk-1 ameliorates chondrocyte apoptosis, cartilage destruction, and subchondral bone deterioration in osteoarthritic knees. Arthritis Rheum. 2010;62:1393–402.CrossRefPubMed
23.
Bouaziz W, Funck-Brentano T, Lin H, Marty C, Ea H-K, Hay E, et al. Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways. Arthritis Res Ther. 2015;17:24.CrossRefPubMedPubMedCentral
24.
Zhu S, Liu H, Wu Y, Heng BC, Chen P, Liu H, et al. Wnt and Rho GTPase signaling in osteoarthritis development and intervention: implications for diagnosis and therapy. Arthritis Res Ther. 2013;15:1–10. doi:10.​1186/​ar4240.CrossRef
25.
Luyten FP, Tylzanowski P, Lories RJ. Wnt signaling and osteoarthritis. Bone. 2009;44:522–7.CrossRefPubMed
26.
He BC, Gao JL, Zhang BQ, Luo Q, Shi Q, Kim SH, et al. Tetrandrine inhibits Wnt/beta-catenin signaling and suppresses tumor growth of human colorectal cancer. Mol Pharmacol. 2011;79:211–9.CrossRefPubMedPubMedCentral
27.
Zhou X, Li W, Jiang L, Bao J, Tao L, Li J, et al. Tetrandrine inhibits the Wnt/β-catenin signalling pathway and alleviates osteoarthritis: an in vitro and in vivo study. Evid Based Complement Alternat Med. 2013;2013:809579.PubMedPubMedCentral
28.
Takamatsu A, Ohkawara B, Ito M, Masuda A, Sakai T, Ishiguro N, et al. Verapamil protects against cartilage degradation in osteoarthritis by inhibiting Wnt/β-catenin signaling. PLoS One. 2014;9:1–8.CrossRef